Dr. Pasi A. Janne – Mesothelioma Doctor – Assistant Professor of Medicine

Share This:

Harvard Medical School, Dana-Farber Cancer Institute

Lowe Center for Thoracic Oncology

44 Binney Street, Dana 1234

Boston, Massachusetts 02115

Phone: 617.632.6049

Fax: 617.632.5786

Email Address: pjanne@partners.org

Dr. Pasi A. Janne. M.D., PhD, has been in the medical profession for more than 12 years. He practices Internal Medicine and Oncology and he is Assistant Professor of Medicine at Harvard Medical School, Dana-Farber Cancer Institute, in Boston , Massachusetts . He is located in the Medical Oncology/Solid Tumor Oncology Department at the Dana-Farber Cancer Institute (or Lowe Center for Thoracic Oncology). His research interests include the study of epidermal growth factor receptor mutations in non-small cell lung cancer and their impact on the efficacy of EGFR-targeted therapeutic agents.

Dr. Janne received his Medical Degree (M.D.) and PhD from the University of Pennsylvania in Philadelphia , Pennsylvania in 1996. He completed his postgraduate medical training in Internal Medicine, in 2001, at Brigham and Women’s Hospital (BWH) in Boston , Massachusetts . He completed his training in Medical Oncology at Harvard University Dana-Farber Cancer Institute (DFCI) — also in 2001.

Dr. Janne won the Merit Award by the American Society of Clinical Oncology (ASCO) in 2001 and he has numerous published works to his credit. Just a few select publications include:

Greulich H, Chen TH, Feng W, Janne PA, Alvarez JV, Bulmer SE, Zappaterra M, Frank DA, Hahn WC, Sellers WR, Meyerson M. Oncogenic transformation by inhibitor-sensitive and resistant EGFR mutants. PLoS Med 2005;2:e313.

Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. Emergence of a drug resistance mutation in the epidermal growth factor receptor gene in gefitinib-responsive non small cell lung cancer. New Eng J Med 2005;352:786-92.

Mukohara T, Civiello G, Johnson BE, Janne PA. Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma. Oncology 2005;68:500-10.

Mukohara T, Engelman JA, Hanna NH, Yeap BY, Kobayashi S, Lindeman N, Halmos B, Pearlberg J, Tsuchihashi Z, Cantley LC, Tenen DG, Johnson BE, Jänne PA. Differential effects of gefitinib and cetuximab on EGFR mutant non-small cell lung cancers. J Natl Cancer Inst 2005;97:1185-94.

Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.

Tracy S, Mukohara T, Hansen M, Meyerson M, Johnson BE, Janne PA. Gefitinib induces apoptosis in the EGFRL858R non-small cell lung cancer cell line H3255. Cancer Res 2004;64:241-4.